Petros enters waiver/amendment with investors covering Dec 2023 equity awards and warrant terms

Petros Pharmaceuticals, Inc.

Waives breach from Dec 21, 2023 issuance of 348,711 shares/options; deems them Excluded Securities.
Amends Section 4(c) of Warrants clarifying Black Scholes Value rights in Fundamental Transactions.
Waiver and Amendment effective as of December 31, 2023, entered March 21, 2024.
No additional consideration paid to investors; all holders of Preferred Stock and Warrants are party.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Petros Pharmaceuticals, Inc. amended Omnibus Waiver and Amendment with the Investors (effective 2023-12-31).

Action: amendment
Agreement: equity purchase
Counterparty: the Investors
Effective: 2023-12-31

Exact text from the filing

On March 21, 2024, the Company entered into an Omnibus Waiver and Amendment (the “Waiver and Amendment”) with the Investors, effective as of December 31, 2023.

View on SEC.gov

545 material agreements filed in the last 30 days. Browse all material agreements →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-037906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.